Evidence Hub

Astaxanthin Modulates Inflammation in Type 2 Diabetes via Regulation of microRNAs, Lysophosphatidylcholine, and α-Hydroxybutyrate

Sharifi-Rigi A, Zal F, Aarabi MH, Dehghani M, Roustaei Rad N, Taghiyar S

International journal of endocrinology, 2025

25 participants · 1 citation

Abstract

Astaxanthin is a carotenoid compound that has several beneficial qualities, including antioxidant, anti-inflammatory, antiapoptotic, and antidiabetic effects. This study examined the effects of astaxanthin supplementation on inflammation-related microRNAs, lysophosphatidylcholine, and α-hydroxybutyrate in individuals with Type 2 diabetes. Fifty people with Type 2 diabetes volunteered in a placebo-controlled, randomized, double-blind clinical trial. Subjects were randomly determined to consume either 10 mg of astaxanthin (n = 25) or a placebo (n = 25) for 12 weeks. Quantitative real-time PCR was employed to assess the expression of inflammation-related microRNAs in peripheral blood mononuclear cells both before and after the intervention, and we employed ELISA to ascertain the serum levels of lysophosphatidylcholine and α-hydroxybutyrate. After 12 weeks of supplementation, in comparison with placebo, astaxanthin supplementation resulted in a noteworthy decrease (p p Trial Registration: Iranian Registry of Clinical Trials (IRCT): IRCT20190305042939N1.

How strong is the evidence?

Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 25 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free